In the original article, there was an error. We forgot to mention the use of the TREK1-3G construct in previous studies reporting similar results. Two corrections have been made. The first correction has been made to section Results, sub-section Openers and pCt Have Allosteric Effects on the Channel Activity of TREK1 and TRAAK, paragraph 3:
“Next, we studied the sensitivity of TREK1 and TRAAK to the opener BL1249 (Tertyshnikova et al., 2005). As previously shown, TREK1 is more sensitive to BL1249 than TRAAK (Idrug/Icontrol = 7.7 ± 1.4 vs Idrug/Icontrol = 1.16 ± 0.03, Figures 3, 4B) (Pope et al., 2018). The sensitivity of TRAAKpCtTREK1 to BL1249 is significantly higher than that of TRAAK (Idrug/Icontrol = 2.04 ± 0.31 vs Idrug/Icontrol = 1.16 ± 0.03), and TREK1pCtTRAAK has a lower sensitivity to BL1249 than TREK1 (Idrug/Icontrol = 2.49 ± 0.32 vs Idrug/Icontrol = 7.7 ± 1.4, Figures 3, 4B). Uncoupling pCt/M4 using the 3G-mutation decreases the sensitivity of TREK1 to BL1249 (Idrug/Icontrol = 3.95 ± 0.32 vs Idrug/Icontrol = 7.7 ± 1.4) as shown previously by Pope et al. (2018), but had no effect on that of TRAAK (Idrug/Icontrol = 1.32 ± 0.04 vs Idrug/Icontrol 1.16 ± 0.03, Figures 3, 4B).”
The second correction has been made to section Results, sub-section pCt Affects the Sensitivity of TREK1 and TRAAK to Extracellular pH, paragraph 1:
“TREK1 is activated by intracellular acidification through the E306 residue located in the pCt. The mutant TREK1E306A is resistant to intracellular acidification and less active than TREK1 (Honore et al., 2002). TREK1 is inhibited by extracellular acidification and stimulated by extracellular alkalinisation (Sandoz et al., 2009) (Figures 8A,C). Residues involved in this sensitivity are located on the extracellular side of the channel, close to the outer mouth of the pore. Here, we tested the role of pCt on the sensitivity of TREK1 and TRAAK to external pH. We took advantage of the uncoupling of pCt and M4 in TREK1-3G to test a possible allosteric effect of pCt on the regulation by acidification. Inhibition by extracellular acidification was still observed in TREK1-3G in good agreement with the result reported by Bagriantsev et al. (2012), but the normalized remaining current at pH 7.4 and 6.7 was a bit lower than TREK1 (0.19 ± 0.02 vs 0.31 ± 0.05 at pH 6.7; 0.37 ± 0.02 vs 0.50 ± 0.04 at pH 7.4, Figures 8B,C). Similar results were obtained by neutralizing K315 and E306 within the pCt of TREK1 (Woo et al., 2018). The 3G mutation also altered the sensitivity of TRAAK to extracellular pH (Figures 8D–F). The effect is stronger than on TREK1 with a significant fraction of TRAAK-3G being resistant to acidification (Figure 8F). This shows that extracellular pH and pCt trigger structural rearrangements that converge on a same and unique SF gate. However, the allosteric effects are less pronounced than between openers and pCt, suggesting multiple conformational states not equally responsive to extracellular and intracellular stimuli.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
two-pore domain potassium channels, pore gating, openers, allostery, extracellular pH
Citation
Choveau FS, Ben Soussia I, Bichet D, Chatelain FC, Feliciangeli S and Lesage F (2021) Corrigendum: Convergence of Multiple Stimuli to a Single Gate in TREK1 and TRAAK Potassium Channels. Front. Pharmacol. 12:795920. doi: 10.3389/fphar.2021.795920
Received
15 October 2021
Accepted
01 November 2021
Published
17 November 2021
Volume
12 - 2021
Edited and reviewed by
Bernard Attali, Tel Aviv University, Israel
Updates
Copyright
© 2021 Choveau, Ben Soussia, Bichet, Chatelain, Feliciangeli and Lesage.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Florian Lesage, lesage@ipmc.cnrs.fr
This article was submitted to Pharmacology of Ion Channels and Channelopathies, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.